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Background: mTOR, which can form mTOR Complex 1 (mTORC1) or mTOR Complex 2 (mTORC2) depending on its
binding partners, is frequently deregulated in the pulmonary neoplastic conditions and interstitial lung diseases of
the patients treated with rapalogs. In this study, we investigated the relationship between mTOR signaling and
epithelial mesenchymal transition (EMT) by dissecting mTOR pathways.
Methods: Components of mTOR signaling pathway were silenced by shRNA in a panel of non-small cell lung
cancer cell lines and protein expression of epithelial and mesenchymal markers were evaluated by immunoblotting
and immunocytochemistry. mRNA level of the E-cadherin repressor complexes were evaluated by qRT-PCR.
Results: IGF-1 treatment decreased expression of the E-cadherin and rapamycin increased its expression, suggesting
hyperactivation of mTOR signaling relates to the loss of E-cadherin. Genetic ablation of rapamycin-insensitive
companion of mTOR (Rictor), a component of mTORC2, did not influence E-cadherin expression, whereas genetic
ablation of regulatory-associated protein of mTOR (Raptor), a component of mTORC1, led to a decrease in
E-cadherin expression at the mRNA level. Increased phosphorylation of AKT at Ser473 and GSK-3β at Ser9 were
observed in the Raptor-silenced NSCLC cells. Of the E-cadherin repressor complexes tested, Snail, Zeb2, and Twist1
mRNAs were elevated in raptor-silenced A549 cells, and Zeb2 and Twist1 mRNAs were elevated in Raptor-silenced
H2009 cells. These findings were recapitulated by treatment with the GSK-3β inhibitor, LiCl. Raptor knockdown
A549 cells showed increased expression of N-cadherin and vimentin with mesenchymal phenotypic changes.
Conclusions: In conclusion, selective inhibition of mTORC1 leads to hyperactivation of the AKT/GSK-3β pathway,
inducing E-cadherin repressor complexes and EMT. These findings imply the existence of a feedback inhibition loop
of mTORC1 onto mTORC2 that plays a role in the homeostasis of E-cadherin expression and EMT, requiring caution
in the clinical use of rapalog and selective mTORC1 inhibitors.
Keywords: mTOR, mTORC1, mTORC2, E-Cadherin repressor complexes, Raptor, Rictor, EMT* Correspondence: yschang@yuhs.ac
1Department of Internal Medicine, Yonsei University College of Medicine,
50-1, Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea
Full list of author information is available at the end of the article
© 2014 Kim et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kim et al. Respiratory Research 2014, 15:26 Page 2 of 9
http://respiratory-research.com/content/15/1/26Background
mTOR, a serine/threonine protein kinase regulating cell
growth and proliferation, transcription, and protein syn-
thesis, is frequently hyperactivated in neoplastic conditions,
tuberous sclerosis complexes (TSC), and lymphangioleio-
myomatosis (LAM) [1]. mTOR combines with other pro-
teins to form two different complexes, mTOR complex 1
(mTORC1) and mTORC2. mTORC1 comprises mTOR,
mLST8/GβL, regulatory-associated protein of mTOR
(Raptor), and PRAS40, while mTORC2 is composed of
mTOR, mLST8/GβL, rapamycin-insensitive companion
of mTOR (Rictor), mSin1, and Protor [2,3]. mTORC1 is
activated by various growth factors and nutrients, and
phosphorylates ribosomal S6 kinase1 (S6K1) and eIF-4E-
binding proteins (4E-BP1 and 4E-BP2), leading to transla-
tion initiation and protein synthesis. mTORC2 regulates
Akt and serum/glucocorticoid regulated kinase 1 (SGK1),
controlling cell survival and proliferation [2,4].
There are clinical evidences suggesting deregulation
of the mTOR pathway may be involved in the epithelial-
mesenchymal transition (EMT). LAM, a rare disease char-
acterized by functional loss of the TSC2 gene leading to
aberrant hyperactivation of the mTOR pathway, exhibits
loss of E-cadherin expression and uncontrolled expression
of smooth muscle actin, implying that the mTOR pathway
may be involved in EMT [5]. Interstitial lung disease and
nephritis, which are frequently observed during treat-
ment with mTOR inhibitors in solid organ transplant
recipients and cancer patients, may be another clues indi-
cating relationship between mTOR pathway and EMT
(Figure 1A) [6,7].
Two mechanisms of rapamycin-induced pneumonitis
have been proposed: direct alveolar cytotoxicity and
immune-mediated toxicity [6]. The direct alveolar cyto-
toxicity hypothesis is based on the observation that the
incidence of interstitial pneumonitis is dose-dependent,
whereas the immune-mediated toxicity hypothesis is
based on the wide range of time courses observed and
the wide range of trough serum levels of rapamycin.
However, mechanistic explanations of these hypotheses
are elusive. Detailed identification of the underlying
mechanisms of mTOR inhibitor-induced EMT requires
dissecting the inherent function of each mTOR complex
with analysis of the pharmacodynamics and pharmaco-
kinetics of mTOR inhibitors.
One possible explanation relating EMT and mTOR
pathway would be disruption of feedback regulation of
Akt by mTORC1. IGF-1 mediates upregulation of the
E-cadherin transcriptional repressors, Snail and Slug,
and pharmacologic inhibition of mTOR inhibits IGF-
1-induced E-cadherin loss [8]. Akt is activated either
by phosphorylation at Thr 308 by phosphoinositide-
dependent kinase 1 (PDPK1) or at Ser473 by mTORC2
[4]. The feedback inhibition of Akt by mTORC1 ismediated by destabilization of IRS1 [9,10] or Grb10 [11].
mTOR inhibitors have been tested in clinical trials
against cancer and for management of LAM, but the
feedback activation of the PI3K-Akt pathway, which oc-
curs with mTORC1 inhibition, might had lessen their clin-
ical utility [11-14].
In this study, we sought to determine the effect of each
mTORC on the expression of E-cadherin. To achieve this,
we selectively deleted Raptor and Rictor, the regulatory
complexes of mTORC1 and mTORC2, respectively. De-
creased E-cadherin was observed in Raptor-silenced cells
whereas no change in E-cadherin was observed in Rictor
and TSC2-silenced cells. Increased phosphorylation of
Akt and GSK-3β was observed in Raptor-deleted cells
leading to up-regulation of E-cadherin repressor com-
plexes. These findings suggest that selective inhibition of
mTORC1 would lead to EMT, which might be the under-
lying mechanism of intestinal pneumonitis and nephritis
in patients treated with rapalogs.
Materials and methods
Antibodies, cells, and plasmids
A549 cells were purchased from ATCC (Manassas, VA,
USA), and 293FT cells were purchased from Invitrogen
(Gaithersburg, MD, USA). H2009, H596, and H1650
cells were obtained from the Korean Cell Line Bank
(Seoul, Korea). pLKO.1-Raptor 1 shRNA (plasmid
#1857), −Raptor 2 shRNA (plasmid #1858), −Rictor 1
shRNA (plasmid #1853), −Rictor 2 shRNA (plasmid
#1854), −TSC2 shRNA (plasmid #15478), psPAX2 (plas-
mid #12260), and pMD2. G (plasmid #12259) were ob-
tained from Addgene (Cambridge, MA, USA). Antibodies,
unless otherwise stated, were obtained from Cell Signaling
Technology and are listed in Additional file 1: Table S1
(Danvers, MA, USA).
Patients’ characteristics
Clinical information of the 305 patients, who had taken
rapalogs under the diagnosis of neoplastic diseases
(n = 198) or solid organ transplantation recipient (n = 107)
between September 2009 and September 2013, was retro-
spectively reviewed. Patients’ diagnoses are as follows:
renal cell carcinoma (n = 151), thyroid cancer (n = 21),
malignant lymphoma (n = 10), neuroendocrine carcinoma
(n = 7), hepatocellular carcinoma (n = 5), breast cancer
(n = 2), and rectal cancer (n = 2). All the solid organ trans-
plantation recipients had taken rapamycin under the
diagnosis of kidney recipient (Table 1). Rapalog-induced
interstitial pneumonitis was identified by radiologic
diagnosis of chest CT images with exclusion of pul-
monary infection or other cause of pulmonary infil-
tration. Chest CT scan was performed at the onset of
respiratory symptoms and signs, not routinely serial
follow up exam. Inclusion criteria for drug-induced
Figure 1 Involvement of the mTOR pathway in the expression of E-cadherin and components of the adherens junctional complex.
(A) Representative chest computed tomographic imaging of 67-years old female patient, who had taken rapalog for 3 months under the
diagnosis of metastatic recurred breast cancer. Compared with imaging prior to the rapalog treatment (left), size of multiple metastatic nodules
(arrows) were decreased but ground glass opacity with interstitial thickenings were newly developed throughout the lung fields (right). (B) A549
cells were treated with 100 ng/mL IGF-1 for the indicated time, and expression of E-cadherin was evaluated by immunoblotting. A549 cells were
treated with the indicated dose of IGF-1 for 16 hr and expression of E-cadherin was evaluated by immunoblotting (C) and qRT-PCR (D). (E) A549
cells were treated with the indicated dose of rapamycin for 16 hr and expression of E-cadherin was evaluated by immunoblotting. (F) A549, H596,
and H2009 NSCLC cells were treated with 100 nM rapamycin for 16 hr and E-cadherin mRNA was evaluated by qRT-PCR. (G) A549 and H596 NSCLC
cells were treated with 100 nM of rapamycin for 16 hr and expression of the components of the adherens junction complex were evaluated by
immunoblotting. Data was analyzed by one-way ANOVA followed by Tukey’s multiple comparison test (D) or an independent sample t-test
(F). β-actin was used as a loading control. RQ: relative quantitation, Rapa: rapamycin, veh: vehicle. Error Bars, SD of 3 independent experiments;
*, P < 0.05; †, P < 0.01.
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followed by the suggestion of Endo et al. [15]. The
use of clinical information received exemption from
IRB deliberation.
shRNA and siRNA experiments
Lentiviral shRNAs were generated as described else-
where [16]. Cells transduced with pLKO.1 lentiviral vec-
tor were maintained in RPMI medium containing 5% fetal
bovine serum. Puromycin (1.0 μg/mL) was added for
A549 and H1650 cells, while concentrations of 2.0 μg/mL
and 3.0 μg/mL were used for H460 and H1299 cells,
respectively.Western blotting
Cells were harvested using 2X LSB lysis buffer contain-
ing protease inhibitor cocktail and phosphatase inhibitor
cocktail (Sigma, St. Louis, MO, USA) on ice. After sonic-
ation, BCA protein assay reagent (Thermo Scientific,
Rockford, IL, USA) was used for protein quantification.
Protein lysates (30–50 μg) were separated by gel electro-
phoresis on 7.5% to 12% polyacrylamide gels and ana-
lyzed by western blot using nitrocellulose membranes
(Bio-Rad Laboratories, Inc., Richmond, CA, USA). Expres-
sion level of each protein was measured using ImageJ
(http://imagej.nih.gov/ij/) and quantified relative to that of
β-actin.
Table 1 Clinical characteristics of the rapalogs induced interstitial pneumonitis
Medication No. of cases No. of interstitial
pneumonitis (%)
Grade 3-4 (%) Time to
development (months)
Neoplastic disease Everolimus 107 7 (6.5) 3 (2.8) 5.8
Temsirolimus 91 4 (4.4) 1 (1.1) 4.6
Solid organ transplantation Rapamycin 107 5 (4.7) 3 (2.8) 8.6
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5 × 105 cells were plated in 6-well plates containing a
sterilized coverslip. The next day, cells were fixed with
4% formaldehyde in PBS, incubated in blocking solution
containing 5% BSA in PBS, and then anti-E-cadherin
mouse (1:100) and anti-Vimentin rabbit antibodies (1:200)
were added for 16 hr. The next day, cells were washed
and anti-mouse IgG (Alexa Fluor 555 conjugate) and
anti-rabbit IgG (Alexa Flour 488 conjugate, Cell Sig-
naling Technology) secondary antibodies were added. Nu-
clei were counterstained with DAPI (1:1000, Sigma) in
PBS and imaged using an LMS510 confocal microscope
(Carl Zeiss, Oberkochen, Germany).
Quantitative real time (qRT)-PCR
Total RNA was extracted using TRI Reagent® (Ambion,
Austin, TX, USA). Reverse transcription and quantitative
PCR were performed using High Capacity cDNA reverse
transcriptase and TaqMan® FastUniversal PCR Master
Mix (2X), respectively. qRT-PCR analysis was conducted
using TaqMan® gene expression assay reagents, and the
StepOnePlus Real-Time PCR system (Applied Biosys-
tems, Carlsbad, CA, USA) with an inventoried primer-
probe set described in Additional file 2: Table S2. IPO8
was amplified in a primer-limited fashion using primers
labelled with VIC dye as an endogenous control.
Statistical analysis
Data were analyzed either by one-way ANOVA followed
by Tukey’s multiple comparison test or an independent
sample t-test. All statistical analyses were two-tailed.
Results
Involvement of the mTOR pathway in the loss of
E-cadherin expression
During the recent 4 years, 16 (5.2%) out of 305 patients,
who had taken rapalogs under the diagnosis of either
neoplastic diseases or solid organ recipient, experienced
clinically apparent interstitial lung disease in the study
institutes (Figure 1A and Table 1). Among them, 7 pa-
tients showed severe interstitial pneumonitis (grade ≥ 3).
The mean time to development of interstitial pneumon-
itis was 6.4 months (5.8 months for everolimus, 4.6 for
temsirolimus, and 8.6 for rapamycin). Together with the
loss of E-cadherin expression in the LAM, development
of interstitial pneumonitis during rapalogs treatmentbrought us a question whether aberration mTOR signal-
ing impacts the expression of E-cadherin and EMT.
To explore this, A549 cells were treated IGF-1 and ex-
pression of E-cadherin was evaluated by immunoblotting.
Treatment with IGF-1 decreased E-cadherin expression in
time- and dose-dependent experiments, and E-cadherin
expression was more dependent on time, reaching a nadir
at 48 hr after IGF-1 treatment (Figure 1B and C). There
was a dose-dependent decrease in E-cadherin mRNA with
IGF-1 treatment, suggesting that the loss of E-cadherin
occurred at the transcriptional level (Figure 1D). Next,
NSCLC cells were treated with rapamycin, an mTOR
inhibitor, and expression of E-cadherin was evaluated
by immunoblotting. Treatment with rapamycin clearly
increased E-cadherin protein and mRNA expression
(Figure 1E,F and G). We also examined the effect rapamy-
cin on the expression of other components of the adhe-
rens junction complex by immunoblotting. Inhibition of
the mTOR pathway with rapamycin increased expression
of E-cadherin, β-catenin, catenin-δ-1, and α-E-catenin
(Figure 1G). Taken together, these findings suggest that
the mTOR pathway is involved in regulating the expres-
sion of E-cadherin and the other components of adherens
junction complex.
Disruption of mTORC1 activity by transduction with
Raptor shRNA inhibits E-cadherin expression
Since recent reports indicate that mTOR functions as a
part of mTORC1 or mTORC2 depending on its binding
partners, and each complex has different inherent roles,
we questioned whether loss of E-cadherin is mediated
through mTORC1 or mTORC2. To investigate this, A549
cells were transduced with shRNA against Raptor, Rictor,
or TSC2, which regulate mTORC1, mTORC2 and Rheb,
respectively. Samples were then blotted for E-cadherin.
Raptor shRNA-transduced cells lost E-cadherin expres-
sion, while Rictor and TSC2 shRNA-transduced cells did
not (Figure 2A). To further confirm this finding, different
Raptor shRNA constructs were transduced into A549 and
H2009 NSCLC cells and the expression of E-cadherin
was evaluated by immunoblotting and real-time PCR.
E-cadherin expression decreased in A549 and H2009
cells when they were transduced with either Raptor shRNA
construct, and the loss was more prominent in A549 cells
(Figure 2B). E-cadherin mRNA expression also decreased
in A549 and H2009 cells transduced Raptor shRNA
Figure 2 Disruption of mTORC1 suppresses E-cadherin expression. (A) A549 cells were stably transduced with lentiviral shRNA vectors
targeting Raptor, Rictor, or TSC2. Expression of E-cadherin was analyzed by Western blotting. (B) A549 and H2009 cells were transduced with 2
different pLKO.1-Raptor-shRNA constructs and expression of E-cadherin was analyzed using Western blotting. (C) E-cadherin mRNA was analyzed
by qRT-PCR in Raptor-silenced A549 and H2009 cells. Data was analyzed by one-way ANOVA followed by Turkey’s multiple comparison test.
β-actin was used as a loading control. Error Bars, SD of 3 independent experiments; RQ, relative quantitation; *, P < 0.05; †, P < 0.01.
Figure 3 Aberrant Akt-GSK3β signaling in Raptor-silenced cells.
A549, H2009, H460, and H1299 NSCLC cells were transduced with
scrambled or Raptor shRNA and pAKT-Ser473 and pGSK-Ser9 levels
were evaluated by Western blotting. β-actin was used as a
loading control.
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by silencing Raptor reduces E-cadherin expression at the
transcriptional level.
Aberrant Akt-GSK-3 signaling in Raptor deficient cells
Because feedback regulation of pAkt is one of the func-
tions of mTORC1, we next evaluated the phosphoryl-
ation of Akt at Ser473 in Raptor-silenced NSCLC cells.
Increased phosphorylation of Akt at Ser473 was ob-
served in A549, H2009, H460, and H1299 Raptor-silenced
NSCLC cells, causing inhibitory phosphorylation of the Akt
substrate GSK-3β at Ser9 (Figure 3). To further confirm hy-
peractivation of Akt/GSK-3β signaling in Raptor-silenced
NSCLC cells, siRNA against Raptor was introduced into
A549, H460, H1299, and H2009 NSCLC cells (data not
shown). All NSCLC cells treated with Raptor siRNA
showed increased levels of pAKT-Ser473 and pGSK-Ser9
compared to those transduced with scrambled siRNA.
These findings suggest that Akt/GSK-3β pathway aberra-
tions are a general finding in cells with mTORC1 dis-
rupted by Raptor silencing and that Akt phosphorylation
leads to functional activation of Akt/GSK-3β signaling.Transcriptional repressors of E-cadherin are elevated in
Raptor-silenced cells
Because transcriptional inhibition of E-cadherin is fre-
quently mediated by E-cadherin repressor complexes and
we observed decreased E-cadherin mRNA expression in
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pressor complex mRNA expression by qRT-PCR. Among
the E-cadherin repressor complexes tested, Snail, Zeb2,
and Twist1 had increased expression in Raptor-silenced
A549 cells and Zeb2 and Twist1 were elevated in Raptor-
silenced H2009 cells (Figure 4A). We postulated that in-
hibitory phosphorylation of GSK-3β at Ser9 by Akt might
cause the increase in Snail, Zeb2, and Twist mRNA. To
test this, A549 parental cells were treated with LiCl, a
GSK-3β inhibitor, and E-cadherin repressor complex
mRNA expression was evaluated by qRT-PCR. Indeed
Snail, Zeb2, and Twist1 mRNAs were elevated in cells
treated with LiCl (Figure 4B). Because Snail is mainly reg-
ulated by β-TrCP mediated proteosomal degradation sec-
ondary to GSK-3β-mediated phosphorylation [17], we
were curious about the contribution of the mRNA level
elevation to the expression of Snail protein. LiCl treatment
slightly increased the expression of Snail and its effect was
comparable to that of IGF-1. Combined treatment with
LiCl and MG132 strongly increased expression of Snail.
Taken together, these findings suggest involvement AKT/
GSK-3β signaling in the loss of E-cadherin repressor com-
plexes in Raptor-silenced cells (Figure 4C).Figure 4 E-cadherin repressor complexes are elevated in Raptor-silen
or Raptor shRNA and E-cadherin repressor complex mRNAs were evaluated
treated with 40 mM LiCl for the indicated times and E-cadherin repressor c
one-way ANOVA followed by Tukey’s multiple comparison test. (C) A549 ce
(10 ng/mL) for 6 hr and expression of Snail was evaluated by immunoblott
independent experiments; RQ, relative quantitation; *, P < 0.05; †, P < 0.01.EMT in Raptor-silenced NSCLC cells
EMT entails morphological and phenotypic changes of
epithelial cells leading to loss of cellular polarity and
intercellular adhesion, and the development of migra-
tory and invasive properties. Phase-contrast imaging of
Raptor-silenced cells shows a transition from the typical
cobblestone appearance to elongated spindle shapes.
These findings are more prominent in A549 cells than
in H2009 cells. To further elucidate the EMT in Raptor-
silenced cells, immunocytochemical staining against
E-Cadherin and Vimentin was performed. Raptor-
silenced A549 cells showed a marked increase in Vimen-
tin and decrease in E-cadherin expression whereas H2009
cells did not exhibit changes in the expression of E-
cadherin and Vimentin (Figure 5A). Then mesenchymal
markers, α-smooth muscle actin (SMA), Vimentin, and
N-cadherin, were blotted in scrambled- and Raptor-
shRNA-transduced cells. Similar to the findings in the
morphologic study, Raptor-silenced H2009 cells did
not show changes in the expression of Vimentin, N-
cadherin, and SMA. Expression of Vimentin and N-
cadherin was increased in Raptor-silenced A549 cells
while that of SMA was unchanged, suggesting thatced cells. (A) A549 and H2009 cells were transduced with scrambled
by qRT-PCR. Data were analyzed by the t-test. (B) A549 cells were
omplex mRNAs were evaluated by qRT-PCR. Data were analyzed by
lls were treated with MG132 (10 μM) and LiCl (40 mM), and/or IGF
ing. β-actin was used as a loading control. Error Bars, SD of 3
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cells (Figure 5B).
Discussion
Since the discovery of rapamycin in 1975 as an anti-
biotic, rapamycin and its derivatives, rapalogs, have been
widely used as immunomodulators in solid organ trans-
plant patients, for the treatment of LAM [13] and Tu-
berous Sclerosis Complex [18], and for the treatment of
neoplastic conditions such as Kaposi’s sarcoma [19], he-
patocellular carcinoma [20], and renal cell carcinoma.
Rapamycin also prolonged the life expectancy of mice
[21] and explosively broadens its clinical applications. In
addition to the common side effects, such as impaired
glucose metabolism and changes in lipid profiles, rapa-
logs can cause interstitial pneumonitis and nephritis.
Pulmonary side effects, including interstitial pneu-
monitis, bronchiolitis obliterans organizing pneumo-
nia, granulomatous interstitial pneumonitis and rarely,Figure 5 EMT in Raptor-silenced cells. (A) Phase contrast and immunoc
and H2009 cells (X1,000). E-cadherin: Red, Vimentin: Green. (B) Expression o
were evaluated in scrambled and Raptor shRNA-transduced A549 and H20
(C) Illustration of the role of mTORC1 in the regulation of mTORC2-mediatediffuse alveolar damage with alveolar hemorrhage [22-24],
are frequent adverse effects of rapalogs and its incidence
is 5-15% [25,26]. There are 2 hypotheses for rapamycin-
induced pneumonitis: direct alveolar cytotoxicity and
immune-mediated toxicity [6]. However, histopathological
analysis of rapamycin-induced lung injury, showing accu-
mulation of extracellular matrix collagen and fibroblast
proliferation, suggests that EMT could be another me-
chanism of rapalog-induced lung injury [27].
The downregulation of E-cadherin is a hallmark of
EMT and is involved in transcriptional repressors, in-
cluding the zinc finger proteins, Snail, Slug, Zeb1, and
Zeb2, and the basic helix-loop-helix factors, TCF3 and
Twist1. Snail and Slug are up-regulated at the transcrip-
tional level by activation of PI3K/Akt/mTOR signaling [8].
They are further controlled by GSK-3β phosphorylation-
mediated degradation [17,28]. In our study, silencing of
Raptor caused increased phosphorylation of Akt at Ser473
and subsequent inhibitory phosphorylation of GSK3β atytochemical image of scrambled and Raptor shRNA-transduced A5549
f EMT markers α-smooth muscle actin (SMA), Vimentin, and N-cadherin
09 cells by Western blotting. β-actin was used as a loading control.
d EMT.
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Zeb2, and Twist1. These findings could be recapitulated
by treatment with GSK-3β inhibitor, resulting in profound
effects on the mRNA expression of E-cadherin repressor
complexes. Among the cells expressing E-cadherin that
were evaluated in this study (A549, H596, H1650, and
H2009), A549 cells showed the most prominent morpho-
logic and phenotypic changes after Raptor silencing. We
postulated these from the characteristics of A549 cells that
have a loss of LKB1 which leads dependency to mTORC1.
Comparing to the silencing of Raptor that caused loss
of mTORC1 mediated feedback inhibition of pAKT-
Ser473 and decrease of E-cadherin expression, rapamy-
cin treatment increased that of E-cadherin. In our time
and dose dependent experiments, treatment of rapamy-
cin showed a prompt decrease in pS6 phosphorylation
within 10 min and a delayed decrease in phosphorylation
of Akt at Ser 473 (Additional file 3: Figure S1). These
findings are compatible to the findings from Montero
et al. [29] and implies that exposure to the higher dose
and/or prolonged exposure to rapamycin inhibits both
mTORC1 and mTORC2 leading inhibition of both
mTORCs, which resulting inhibition of pAkt-Ser473 and
increase of E-cadherin expression. The half-life of rapa-
mycin in whole blood is 135 hr (vs. 7.2 hr in plasma) in
humans [30]. The usual dose of rapamycin ranges from
1 to 3 mg/day and is adjusted to maintain trough levels
of 4 to 12 ng/mL [26]. It is unclear whether repetitive oral
administration of 1 to 3 mg/day of rapamycin to adults is
mTORC1 selective or influences both mTORCs. These
suggest further in vivo studies are required with cautious
dosing schedules and optimal dosing ranges.
Our study has a number of limitations. Besides that
animal data was not presented, findings in this study
were obtained from lung cancer cell lines. When com-
pared to the silencing of the Rictor, which did not result
in noticeable changes in cell proliferation, disruption of
mTORC1 by Raptor silencing significantly inhibited cell
growth and proliferation. Transduction of Raptor shRNA
into BEAS-2B cells inhibited cell proliferation and re-
sulted in failure of cell line establishment. This may ori-
ginate not only from the unique role of each mTOR
complex but also from the existence of alternative path-
ways which circumvent blocking of the each pathway.
In other words, relayed signaling through PI3K-PDK1
pathway may be helpful to circumvent the blocking of
mTORC2 whereas there is no alternative pathway which
helps bypassing blocking of mTORC1. This bypass of
mTORC2 blocking led less phenotypic changes in Rictor
silenced cells. We also were unable to observe changes in
E-cadherin in TSC2-suppressed cells. Because loss of TSC
function is still considered a major mechanism that leads
to uncontrolled proliferation of LAM cells, further study
on this subject is warranted.Conclusions
Selective inhibition of mTORC1 induced phosphory-
lation of AKT Ser473 and GSK-3β Ser9, increasing expres-
sion of E-cadherin repressor complexes and decreasing
expression of E-cadherin. This finding suggests caution
in using selective mTORC1 inhibitors and/or p70S6K1
inhibitors in clinical practice because of the danger of
AKT-mediated EMT (Figure 5C).
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Additional file 2: Table S2. List of Taqman primers and probes used in
this study.
Additional file 3: Figure S1. Dose and time effect of rapamycin on the
mTOR pathway. A549 cells were treated with vehicle, 1, and 10 nM of
rapamycin for the indicated times and expression of pAkt-Ser473 and
p-GSK3β Ser9, and pS6 Ser235/236 were evaluated by immunoblotting.
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